Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the ...

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO, January 09, 2025--Biocom California, the association representing the California life science industry, today announced that it appointed Aliza ...

Annual Meeting and Exposition taking place Dec. 7-10 in San Diego. Eli Lilly and Company (NYSE: LLY) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective ...

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

World stocks were mixed on Wednesday following Wall Street’s mostly positive performance before key U.S. inflation data that ...

Dr. Buchanan will helm Belharra’s research organization as the company progresses its lead immunology and oncology programs, advances activities ...

Cool wholesale inflation numbers provide only slight relief before Wednesday's release of December Consumer Price Index data.

Andy Extance charts how research into revolutionary targeted protein degradation therapies is moving from serendipity to ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...